Companies › Incepta Pharmaceuticals
1 active drug program in 8 registered trials: 5 Phase 3, 2 Phase 4, 1 Phase 1; Neurology, Hematology, Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Epoetin Alfa Erythropoietin receptor agonist | EPOR | Phase 3 | Healthy; Hypobaric Hypoxia; Anemia; Encephalopathy … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05300477 | Epoetin Alfa | Phase 4 | Hypobaric Hypoxia | Other | Sep 2023 |
| NCT07025681 | Epoetin Alfa | Phase 3 | Healthy | Other | Sep 2025 |
| NCT05395195 | Epoetin Alfa | Phase 3 | Encephalopathy | Neurology | Dec 2026 |
| NCT06670963 | Epoetin Alfa | Phase 4 | Anemia | Hematology | Dec 2026 |
| NCT04588311 | Epoetin Alfa | Phase 3 | Trauma | Neurology | Dec 2026 |
| NCT00843882 | Epoetin Alfa | Phase 3 | Anemia | Hematology | May 2027 |
| NCT03223961 | Epoetin Alfa | Phase 3 | Myelodysplastic Syndromes | Hematology | Oct 2028 |
| NCT06832189 | Epoetin Alfa | Phase 1 | Liver Transplant | Other | Jun 2030 |
Chongqing Claruvis Pharmaceutical Kedrion CellTherX Pharmazz Sandoz
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.